At 7.6% CAGR, North America Gastrointestinal Drugs Market is Projected to be Worth US$ 43,362.58 Million by 2031, Says Business Market Insights

According to Business Market Insights' research, the North America gastrointestinal drugs market was valued at US$ 24,104.40 in 2023 and is expected to reach US$ 43,362.58 million by 2031, registering a CAGR of 7.6% from 2023 to 2031. Rising cases of gastrointestinal diseases and increasing development of biologics are among the critical factors attributed to the North America gastrointestinal drugs market expansion.

Gastrointestinal diseases are conditions that occur in the gastrointestinal tract. Common digestive problems include heartburn, inflammatory bowel diseases (IBD), inflammatory bowel syndrome (IBS), gastroenteritis, gastroesophageal reflux disease (GERD), constipation, diarrhea, etc. Gastrointestinal diseases are common chronic inflammatory conditions that affect an enormous population worldwide. This is due to a sedentary lifestyle, changing dietary habits, and stress, among other factors. Also, the incidence and prevalence of gastrointestinal diseases are higher in adults, and as the population ages, the disease burden is also expected to increase.

According to the study, “Gastroesophageal Reflux Disease,” published in July 2023, GERD is one of the most prevalent diagnosed gastrointestinal conditions, affecting 20% of the people, resulting in major economic burden in direct and indirect costs and adversely impacting the quality of life.

Per the same source, the expected prevalence of GERD in the US ranges between 18.1% and 27.8%. Western countries such as the US, Canada, and the UK are witnessing a high gastrointestinal disease incidence rate due to growing obesity among the adult population, along with less consumption of dietary fiber.

As per the study, “How Particle’s Specialty Search Addresses Different Health Conditions,” published in February 2023, digestive diseases rank third among illnesses in overall economic expense in the US, costing an estimated total of US$ 136 billion in annual healthcare expenditures with more hospitalizations than any other condition. In addition, 62 million Americans are diagnosed with digestive disorders each year.

The incidence and prevalence of IBD have increased in the last few decades worldwide due to poor nutritional choices, including a high intake of ultra-processed foods and trans-fats. IBD is a chronic inflammation of the digestive tract and refers to two conditions: ulcerative colitis and Crohn's disease. As per the Crohn's & Colitis Foundation of America, ~70,000 new cases of IBD are diagnosed annually in the US.

Furthermore, the incidence and prevalence of IBS have increased in the last few decades globally. As per the International Foundation for Gastrointestinal Disorders, Inc., IBS is the most prevalent functional gastrointestinal disease, with a prevalence rate of 10–15% of the population across the globe. A study conducted by the University of Gothenburg states that for every ten adults in the world, four suffer from functional gastrointestinal disorders of varying severity. In the US, there are approximately 2.4–3.5 million hospital visits for IBS annually. Thus, the rising prevalence of gastrointestinal diseases worldwide fuels the demand for treatment of these conditions, thereby driving the gastrointestinal drugs market.

On the contrary, high cost of biologics hampers the growth of North America gastrointestinal drugs market.

Based on drug class, the North America gastrointestinal drugs market is segmented into biologics, antidiarrheal and laxatives, acid neutralizers, anti-inflammatory drugs, antiemetic and antinauseants and others. The biologics segment held 27.7% share of the North America gastrointestinal drugs market in 2023, amassing US$ 6,673.91 million. It is projected to garner US$ 12,135.30 million by 2031 to expand at 7.8% CAGR during 2023–2031.

By application, the North America gastrointestinal drugs market is segmented into irritable bowel syndrome, inflammatory ulcerative colitis, Crohn’s disease, gastroenteritis, celiac disease and others. The irritable bowel syndrome segment held 30.7% share of the North America gastrointestinal drugs market in 2023, amassing US$ 7,389.13 million. It is projected to garner US$ 13,651.77 million by 2031 to expand at 8.0% CAGR during 2023–2031.

By route of administration, the North America gastrointestinal drugs market is bifurcated into oral and parenteral. The oral segment held 62.2% share of the North America gastrointestinal drugs market in 2023, amassing US$ 14,986.70 million. It is projected to garner US$ 27,882.72 million by 2031 to expand at 8.1% CAGR during 2023–2031.

By distribution channel, the North America gastrointestinal drugs market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment held 45.8% share of the North America gastrointestinal drugs market in 2023, amassing US$ 11,043.95 million. It is projected to garner US$ 20,723.90 million by 2031 to expand at 8.2% CAGR during 2023–2031.

Based on country, the North America gastrointestinal drugs market is segmented into the US, Canada, and Mexico. The US held 82.4% share of North America gastrointestinal drugs market in 2023, amassing US$ 19,867.69 million. It is projected to garner US$ 36,110.46 million by 2031 to expand at 7.8% CAGR during 2023–2031.

Key players operating in the North America gastrointestinal drugs market are Sanofi SA, GSK Plc, Johnson & Johnson, Bausch Health Companies Inc, AstraZeneca Plc, Takeda Pharmaceutical Co Ltd, AbbVie Inc, Bayer AG, Celltrion Inc, and Pfizer Inc, among others.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com